Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 8/20 | 0.44 |
| ▸ | CA1 | P00915 | 7/20 | 0.44 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3565139 | 0.92 | L3MBTL1 (0.59) | L3MBTL1CA2CA1CA7NAMPT | |
| SCHEMBL3562248 | 0.92 | CA2 (0.48) | CA2CA1CA7CCR3ALDH1A1 | |
| SCHEMBL3561058 | 0.90 | CCR3 (0.47) | L3MBTL1CA2CA1CA7CCR3 | |
| SCHEMBL3564369 | 0.90 | CNR1 (0.48) | CA2CA1CNR1POLB | |
| SCHEMBL3565154 | 0.90 | UTS2R (0.46) | CA2CA1CA7CCR3ALDH1A1 | |
| SCHEMBL3562731 | 0.90 | POLB (0.45) | CA2CA1CA7NAMPTCCR3 | |
| SCHEMBL3555505 | 0.89 | CA1 (0.50) | CA2CA1CA7CCR3 | |
| SCHEMBL3556125 | 0.89 | POLB (0.45) | L3MBTL1CA2CA1CCR3ALDH1A1 | |
| SCHEMBL3564906 | 0.87 | CCR3 (0.41) | CA2CA1CA7NAMPTCCR3 | |
| SCHEMBL3556001 | 0.87 | HTR7 (0.41) | CA2CA1CA7CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |